IDN 5390: A new concept in taxane development

Giulia Taraboletti, Gianluca Micheletti, Raffaella Giavazzi, Antonella Riva

Research output: Contribution to journalArticlepeer-review


IDN 5390 is a seco-derivative cytostatic taxane. Originally selected for its ability to affect endothelial cell motility, the anti-angiogenic properties of IDN 5390 have been documented in experimental models, in vivo and in vitro. Preclinical studies indicate that, in vivo, oral IDN 5390 has a favorable bioavailability, is well tolerated and shows a significant anti-neoplastic activity on a panel of different tumor models, including paclitaxel-resistant tumors. According to its cytostatic rather than cytotoxic nature, frequent administrations of non-toxic doses have proven to be the optimal schedule for IDN 5390 treatment. Preliminary findings suggest the use of this compound in combination with conventional anti-neoplastic therapy. IDN 5390 can be considered the prototype of a new class of well-tolerated, orally available anti-angiogenic taxane derivatives with cytostatic properties.

Original languageEnglish
Pages (from-to)255-258
Number of pages4
JournalAnti-Cancer Drugs
Issue number4
Publication statusPublished - Apr 2003


  • Angiogenesis inhibitor
  • Cell motility
  • Cytostatic agent
  • IDN 5390
  • Microtubules
  • Paclitaxel
  • Taxane

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology


Dive into the research topics of 'IDN 5390: A new concept in taxane development'. Together they form a unique fingerprint.

Cite this